Patents by Inventor Francis X. Tavares

Francis X. Tavares has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY
    Publication number: 20180221378
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
  • CDK Inhibitors
    Publication number: 20180201617
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK INHIBITORS
    Publication number: 20180201618
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK INHIBITORS
    Publication number: 20180201619
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 9957276
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: May 1, 2018
    Assignee: GI Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK Inhibitors
    Publication number: 20170057971
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Applicant: G1 THERAPEUTICS, INC.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 9499564
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: November 22, 2016
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 9481691
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: November 1, 2016
    Assignee: G1 THERAPEUTICS, INC.
    Inventors: Francis X. Tavares, Jay C. Strum
  • SMALL MOLECULE C-MYC INHIBITORS
    Publication number: 20160264560
    Abstract: This invention provides small molecule Myc-inhibitors. Also provided in the invention are therapeutic applications of these compounds for treating Myc-driven cancer and other related methods.
    Type: Application
    Filed: December 10, 2014
    Publication date: September 15, 2016
    Inventors: Peter K. VOGT, Francis X. TAVARES, Kim D. JANDA
  • CDK Inhibitors
    Publication number: 20150246925
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: May 14, 2015
    Publication date: September 3, 2015
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK Inhibitors
    Publication number: 20150246926
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: May 14, 2015
    Publication date: September 3, 2015
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 9102682
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: August 11, 2015
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK Inhibitors
    Publication number: 20150031880
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: August 5, 2014
    Publication date: January 29, 2015
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 8829012
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: September 9, 2014
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 8822683
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: September 2, 2014
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK Inhibitors
    Publication number: 20140142306
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: January 23, 2014
    Publication date: May 22, 2014
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK Inhibitors
    Publication number: 20140142299
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Application
    Filed: January 23, 2014
    Publication date: May 22, 2014
    Applicant: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 8691830
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: April 8, 2014
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 8598197
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: December 3, 2013
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum
  • CDK inhibitors
    Patent number: 8598186
    Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: December 3, 2013
    Assignee: G1 Therapeutics, Inc.
    Inventors: Francis X. Tavares, Jay C. Strum